EGFR and small cell lung carcinoma: To identify potential therapeutic vulnerabilities of tumors undergoing NE transformation, we performed a Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-Cas9 drop-out screen over 15 population doublings (21 days) of a short-term in vitro cultured cell line derived from a EGFR-mutant transformed SCLC (T-SCLC) PDX (SCLC-N subtype), previously described in ref. 18 (Fig. 1a).